Assay Development Drug Development Drugs 
PPD
OCTOBER 18, 2023
With the depth of knowledge to support all types of pharmaceutical products across all phases of development, we provide services ranging from end-to-end assay development to platform expansion, designed with the client’s timeline and budget in mind. Stay ahead of the curve with a great GMP/CMC contract laboratory partner.
Sygnature Discovery
JANUARY 17, 2023
Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Alta Sciences
AUGUST 21, 2023
Efficient Characterization of ADME A critical feature of the bioanalytical platform selected for a drug development program is how well it characterizes the ADME (absorption, distribution, metabolism, excretion) of your molecule of interest. Why Partner With Altasciences for Your Bioanalytical Projects?
PerkinElmer
NOVEMBER 12, 2020
In drug development, assays are test systems that gauge the effects of chemical compounds on certain cellular, molecular, or biochemical processes. They are a vital step in modern pharma research that pushes drugs to market faster. These are just three of the steps to take toward reliable and replicable assay development.
FDA Law Blog: Drug Discovery
JANUARY 4, 2023
The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. Similar to the OTAT town hall meeting in September, potency assay requirements and pitfalls were discussed.
Drug Target Review
NOVEMBER 1, 2023
Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.
Drug Target Review
OCTOBER 3, 2024
Since the 1970s, when hybridoma technology enabling the generation of monoclonal antibodies (mAbs) was first developed, 1 antibody-based therapeutics have become one of the most rapidly growing drug categories, with applications across cancer indications, immune disorders and infections.
Expert insights. Personalized for you.
52 
Let's personalize your content